In a report released on June 17, Whit Mayo from Leerink Partners reiterated a Buy rating on BrightSpring Health Services, Inc. (BTSG – Research Report), with a price target of $28.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Whit Mayo has given his Buy rating due to a combination of factors that highlight BrightSpring Health Services, Inc.’s strong growth potential. The company is experiencing robust organizational growth, particularly in its specialty and infusion pharmacy sectors, which are supported by consistent provider demand. The momentum in specialty pharmacy is expected to continue, driven by ongoing generic drug conversions and a strong pipeline, especially in oncology and rare diseases.
Furthermore, the infusion pharmacy segment presents a significant growth opportunity, with management viewing it as a potential 20% annual grower. Strategic investments, including the addition of experienced leadership, are expected to enhance execution in this area. Despite potential policy headwinds from the Inflation Reduction Act, operational efficiencies are likely to mitigate these challenges, reinforcing the company’s growth trajectory.
In another report released on June 17, Bank of America Securities also reiterated a Buy rating on the stock with a $26.75 price target.
BTSG’s price has also changed moderately for the past six months – from $18.460 to $21.350, which is a 15.66% increase.